Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
No new studies have been requested
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
The investment will accelerate the overall Sarclisa development program
New InterStim X system provides 10 to 15 years of battery life without the need to recharge
Subscribe To Our Newsletter & Stay Updated